Thomas D. Bielli, Esquire (Admitted *Pro Hac Vice*) Bielli & Klauder, LLC 1500 Walnut Street, Suite 900 Philadelphia, PA 19102

Telephone: (215) 642-8217 Facsimile: (215) 754-4177

Proposed Counsel to Fee Examiner David M. Klauder, Esquire

## UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re:	Chapter 11
PURDUE PHARMA L.P., et al.,	Case No. 19-23649 (RDD)
Debtors. <sup>1</sup>	(Jointly Administered)

CERTIFICATE OF NO OBJECTION UNDER 28 U.S.C. § 1746 REGARDING APPLICATION OF FEE EXAMINER, PURSUANT TO SECTION 327(a) OF THE BANKRUPTCY CODE, BANKRUPTCY RULE 2014, AND LOCAL BANKRUPTCY RULES 2014-1 AND 2016-1, FOR THE ENTRY OF AN ORDER AUTHORIZING THE RETENTION AND EMPLOYMENT OF BIELLI & KLAUDER LLC AS COUNSEL TO THE FEE EXAMINER, NUNC PRO TUNC TO THE APPOINTMENT DATE (Re: D.I. 1135)

Pursuant to 28 U.S.C. § 1746, Rule 9075-2 of the Local Bankruptcy Rules for the Southern District of New York and in accordance with this Court's case management procedures as set forth in the *Second Amended Order Establishing Certain Notice, Case Management, and Administrative Procedures*, entered on November 18, 2019, the undersigned hereby certifies that as of the date hereof he has received no answer, objection or other responsive pleading to the

El Dia di

<sup>&</sup>lt;sup>1</sup> The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3092), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Application of Fee Examiner, Pursuant to Section 327(a) of the Bankruptcy Code, Bankruptcy Rule 2014, and Local Bankruptcy Rules 2014-1 and 2016-1, for the Entry of an Order Authorizing the Retention and Employment of Bielli & Klauder, LLC as Counsel to the Fee Examiner, Nunc Pro Tunc to the Appointment Date (D.I. 1135) (the "Application"). The undersigned further certifies that he has reviewed the Court's docket in these cases and no answer, objection or other responsive pleading to the Application appears thereon. Pursuant to the Notice affixed to and accompanying the Application, responses were to be filed and served no later than May 18, 2020 at 4:00 p.m. (prevailing Eastern Time).

Accordingly, the Fee Examiner respectfully requests that the Court enter the proposed order, a copy of which is attached hereto as **Exhibit A**, granting the relief requested in the Application.

I hereby declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge, information and belief.

Dated: May 20, 2020 BIELLI & KLAUDER LLC

/s/ Thomas D. Bielli

Thomas D. Bielli, Esquire (Admitted *Pro Hac Vice*) 1500 Walnut Street, Suite 900 Philadelphia, PA 19102

Phone: (215) 642-8271 Fax: (215) 754-4177 tbielli@bk-legal.com

Proposed Counsel to Fee Examiner David M. Klauder, Esquire